Pneumococcal infections and protection with vaccination in adult chronic lung diseases

Basit Öğe Kaydı
dc.contributor.authorKaradeniz, Gulistan
dc.contributor.authorKilinc, Oguz
dc.contributor.authorOlmez, Ayse
dc.contributor.authorOzhan, Mustafa Hikmet
dc.contributor.authorOzlu, Tevfik
dc.contributor.authorOzyurek, Berna Akinci
dc.contributor.authorSayiner, Abdullah
dc.date.accessioned2021-05-03T20:38:40Z
dc.date.available2021-05-03T20:38:40Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractPneumococcal infections are an important cause of mortality and morbidity in Chronic Lung Diseases. However, exacerbations, which make the treatment of diseases very difficult, and corticosteroids used during treatment carry a great risk of pneumococcal infection and adversely affect the treatment. The most rational way to reduce the negative impact of pneumococcal infections on the clinical and economic burden of Chronic Lung Diseases is vaccination of the risky population. Although, vaccination recommendations are well defined, recommended by national and international guidelines and are paid by health authorities, in Turkey, vaccination rates in adults with chronic lung disease is far below the expected. Since physicians are considered to be the most important and reliable resource that can guide their patients in vaccination, applying pneumococcal vaccination routinely in all patients with chronic lung diagnosis and making it a part of daily practice will greatly contribute to reducing the clinical and economic burden of pneumococcal infections in these patients. in this review, the effects of pneumococcal diseases on chronic lung diseases, the risk and clinical burden of pneumococcal diseases in chronic lung diseases are discussed in the light of guidelines and current literature, and the importance of protection from pneumonia in these patients is emphasized. in addition to general information and efficacy data about pneumococcal vaccines available in our country, application methods and access routes to vaccines are also described.en_US
dc.identifier.doi10.5578/tt.70012en_US
dc.identifier.endpage320en_US
dc.identifier.issn0494-1373
dc.identifier.issue3en_US
dc.identifier.pmid33295729en_US
dc.identifier.scopus2-s2.0-85096027247en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage305en_US
dc.identifier.urihttps://doi.org/10.5578/tt.70012
dc.identifier.urihttps://hdl.handle.net/11454/70517
dc.identifier.volume68en_US
dc.identifier.wosWOS:000590890600012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.publisherTurkish Assoc Tuberculosis & Thoraxen_US
dc.relation.ispartofTuberkuloz Ve Torak-Tuberculosis and Thoraxen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic lung diseaseen_US
dc.subjectpneumoniaen_US
dc.subjectTurkeyen_US
dc.subjectpneumococcal vaccineen_US
dc.subjectrisk groupsen_US
dc.titlePneumococcal infections and protection with vaccination in adult chronic lung diseasesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu